Malignant Cervical Neoplasm — Trials

Malignant Cervical Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,994 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 506
Recruiting: 280
Ph III recruiting: 34
Growth YoY: −11.9%
Industry share: 20%
Top sponsor: National Cancer Institute (NCI)
Termination share: 22.7%
Trials / 1,000 deaths: 121.6 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (181)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06952660	Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer	recruiting	Phase 4	100	PfizerINDUSTRY	2	Sep 25, 2026	clinicaltrials
NCT07645625	Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer(PROTECx)	recruiting	Phase 4	261	University Medical Center GroningenOTHER	1	Jun 29, 2026	clinicaltrials